These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 21224796)
1. The role of splenectomy in myelofibrosis with myeloid metaplasia. Barugola G; Cavallini A; Lipari G; Armatura G; Mantovani W; Baggio E Minerva Chir; 2010 Dec; 65(6):619-25. PubMed ID: 21224796 [TBL] [Abstract][Full Text] [Related]
2. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Mesa RA; Elliott MA; Tefferi A Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148 [TBL] [Abstract][Full Text] [Related]
3. Subtotal splenectomy for treatment of patients with myelofibrosis and myeloid metaplasia. Petroianu A Int Surg; 1996; 81(2):177-9. PubMed ID: 8912088 [TBL] [Abstract][Full Text] [Related]
4. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Faoro LN; Tefferi A; Mesa RA Eur J Haematol; 2005 Feb; 74(2):117-20. PubMed ID: 15654901 [TBL] [Abstract][Full Text] [Related]
5. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Mesa RA; Nagorney DS; Schwager S; Allred J; Tefferi A Cancer; 2006 Jul; 107(2):361-70. PubMed ID: 16770787 [TBL] [Abstract][Full Text] [Related]
6. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395 [TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases. Akpek G; McAneny D; Weintraub L J Surg Oncol; 2001 May; 77(1):42-8. PubMed ID: 11344482 [TBL] [Abstract][Full Text] [Related]
8. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases. Brenner B; Nagler A; Tatarsky I; Hashmonai M Arch Intern Med; 1988 Nov; 148(11):2501-5. PubMed ID: 3190384 [TBL] [Abstract][Full Text] [Related]
9. Palliative splenectomy in myelofibrosis with myeloid metaplasia. Mesa RA; Tefferi A Leuk Lymphoma; 2001; 42(5):901-11. PubMed ID: 11697645 [TBL] [Abstract][Full Text] [Related]
10. Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia. Mesa RA; Tefferi A Semin Oncol; 2005 Aug; 32(4):403-13. PubMed ID: 16202686 [TBL] [Abstract][Full Text] [Related]
11. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Barosi G; Ambrosetti A; Buratti A; Finelli C; Liberato NL; Quaglini S; Ricetti MM; Visani G; Tura S; Ascari E Leukemia; 1993 Feb; 7(2):200-6. PubMed ID: 8426474 [TBL] [Abstract][Full Text] [Related]
12. [Severe post-splenectomy hepatic insufficiency in a patient with agnogenic myeloid metaplasia]. Pérez-Villa F; Font J; Feliu E; Campo E; Ingelmo M Med Clin (Barc); 1988 Jun; 91(3):108-10. PubMed ID: 3172909 [No Abstract] [Full Text] [Related]
13. [Splenectomy in myelofibrosis and myeloid metaplasia]. Chaimoff C; Amir J; De Vries A Harefuah; 1974 Sep; 87(5):211-2. PubMed ID: 4435616 [No Abstract] [Full Text] [Related]
14. [Haematological implications of splenectomy in myelofibrosis with myeloid metaplasia (author's transl)]. Domingo Albos A; Pujol Moix N; Madoz Resano P; Cortada Font A; Diaz Cremades J; Algaba Arrea F; Nogueras FM Sangre (Barc); 1976; 21(3):451-60. PubMed ID: 968710 [No Abstract] [Full Text] [Related]
15. Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. Lafaye F; Rain JD; Clot P; Najean Y Nouv Rev Fr Hematol (1978); 1994 Oct; 36(5):359-62. PubMed ID: 7892130 [TBL] [Abstract][Full Text] [Related]
16. Portal hypertension complicating myelofibrosis: reversal following splenectomy. Lukie BE; Card RT Can Med Assoc J; 1977 Oct; 117(7):771-2. PubMed ID: 907949 [TBL] [Abstract][Full Text] [Related]
17. Autoimmune haemolytic anaemia as the presenting manifestation of agnogenic myeloid metaplasia. Mohite U; Pathare A; al Kindi S; Hiwase D; Vadakkepat N; Knox-Macaulay H Haematologia (Budap); 2002; 32(4):495-9. PubMed ID: 12803124 [TBL] [Abstract][Full Text] [Related]